<DOC>
	<DOCNO>NCT00855530</DOCNO>
	<brief_summary>Primary objective : - To evaluate long-term safety tolerability SR58611A ( amibegron ) patient major depressive disorder ( MDD ) . Secondary objective : - To determine plasma concentration SR58878 ( active metabolite SR58611A ) , pharmacokinetic population analysis , evaluate quality life ( QoL ) patient MDD , evaluate efficacy amibegron patient MDD .</brief_summary>
	<brief_title>Long Term Safety Tolerability SR58611 Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>patient define Diagnosis Statistical Manual Mental Disorders , recurrent episode least 1 month prior entry study , total score &gt; 18 Hamilton Depression Rating Scale ( HAMD ) 17items .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Depression</keyword>
</DOC>